There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found

Molecular Interventions

Volumn 5, Issue 2, 2005, Pages 79-83

  Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ALPRAZOLAM; AMIODARONE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CYCLOSPORIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DAPSONE; DEBRISOQUINE; DEXTROMETHORPHAN; ERYTHROMYCIN; ERYTHROMYCIN DERIVATIVE; FEXOFENADINE; HYDROCORTISONE; LIDOCAINE; MEPHENYTOIN; MIDAZOLAM; NIFEDIPINE; OMEPRAZOLE; PHENAZONE; RANITIDINE; SAQUINAVIR; TRIAZOLAM; TROLEANDOMYCIN; UNINDEXED DRUG; VERAPAMIL;

BREATH ANALYSIS; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG METABOLISM; DRUG SOLUBILITY; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; HUMAN; MOLECULAR PROBE; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

ALPRAZOLAM; BENZODIAZEPINES; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; CYTOCHROME P-450 CYP3A; DRUG DESIGN; HUMANS; KINETICS; MIDAZOLAM; MOLECULAR PROBES; PROTEIN BINDING; SOLUBILITY; TRIAZOLAM;

EID: 17844393071     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.5.2.5     Document Type: Review

References (21)

1. Garrett, E.R. Classical pharmacokinetics to the frontier. J. Pharmacokinet. Biopharm. 1, 341-361 (1973).
2. Masica, A.L., Mayo G., and Wilkinson, G.R. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin. Pharmacol. Ther. 76 , 341-349 (2004).
3. Vessell, E.S. and Penno M.B. Assessment of methods to identify sources of interindividual pharmacokinetic variation. Clin. Pharmacokinet. 8, 378-409 (1983).
4. Streetman, D.S., Bertino J.S. Jr., and Nafziger, A.N. Phenotyping of drug-metabolizing enzymes in adults: A review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10, 187-216 (2000).
5. Lamba, J.K., Lin Y.S., Schuetz, E.G., and Thummel, K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54, 1271-1294 (2002).
6. Wu, C-Y. and Benet, L. Z. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22, 11-23 (2005).
7. Amidon, G.L., Lennernas, H., Shah, V.P., and Crison J.R. A theoretical basis for a biopharmaceutics drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420 (1995).
8. Food and Drug Administration. Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system. Food and Drug Administration, Rockville, MD (2000). Available at http://www.fda.gov/cder/guidance/index.htm
9. Tolle-Sander, S., Rautio, J., Wring, S., Polli, J.W., and Polli, J.E. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm. Res. 20, 757-764 (2003).
10. Watanabe, N. and Benet, L.Z. The effect of the interplay between CYP3A4 and P-gp on the metabolism of saquinavir and nifedipine in CYP3A4-transfected Caco-2 cells. Pharmaceutical Sciences World Congress, Kyoto, Japan, June, 2004, Abstract P2E-II-026.
11. Thummel, K.F. and Shen D.D. Design and optimization of dosage regimens: pharmacokinetic data, in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Hardman, J.G. and Limbird, L.E., eds.) pp. 1924-2023, 10th edition, McGraw Hill, New York (2001).
12. Yuan, R., Flockhart, D.A., and Balian, J.D. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J. Clin. Pharmacol. 39, 1109-1125 (1999).
13. Fraser, A.D. Urinary screening for alprazolam, triazolam, and their metabolites with EMIT d.a.u. benzodiazepine metabolite assay. J. Anal. Toxicol. 11, 263-266 (1987).
14. Kharasch, E.D., Walker, A., Hoffer, C., and Sheffels, P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin. Pharmacol. Ther. 76, 452-466 (2004).
15. Kharasch, E.D., Jubert, C., Senn, T, Bowdle, T.A., and Thummel, K.E. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J. Clin. Pharmacol. 39, 664-669 (1999).
16. Kharasch, E.D., Walker, A., Hoffer, C., and Sheffels, P. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. J. Clin. Pharmacol. 45, 79-88 (2005).
17. Fleischer, D., Li, C., Zhou, Y., Pao, L.H., and Karim, A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin. Pharmacokinet. 36, 233-254 (1999).
18. Benet, L.Z., Cummins, C.L., and Wu, C-Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. 277, 3-9 (2004).
19. Lau, Y.Y., Wu, C-Y., Okochi, H., and Benet, L.Z. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: Hepatic enzyme-transporter interplay. J. Pharmacol. Exp. Ther. 308, 1040-1045 (2004).
20. Lam, J. L. and Benet L.Z. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interacations: Studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab. Dispos. 32, 1311-1316 (2004).
21. Lown, K.S., Mayo, R.R., Leichtman, A.B. et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62, 248-260 (1997).